艾美疫苗(06660.HK)今日股价大涨6.55%,主因其控股子公司珠海丽凡达生物技术研发的mRNA呼吸道合胞病毒(RSV)疫苗,于近日获得国家药监局出具的《药物临床试验批准通知书》,标志着该疫苗进入重要的新阶段。
RSV是导致婴儿和老年人呼吸道重症感染和死亡的主要原因之一。目前全球尚无针对RSV可用于临床的抗病毒特效药,接种疫苗成为预防重症感染的有效手段。中国国内尚无RSV疫苗获批上市,全球市场空白巨大。
行业顾问估计,到2030年,全球RSV疫苗市场规模将达约167亿美元。艾美疫苗为国内首家获批RSV疫苗临床试验的企业,如该疫苗成功上市,将极大拓展公司业务版图,成为未来重要业绩增长点,因此公司股价受到资金追捧,出现大涨行情。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.